Losartan

Drug Profile

Losartan

Alternative Names: Cozaar; Cozaarex; DUP 753; Lortaan; Losaprex; Losartan potassium; MK 954; Neo Lotan; Nu-Lotan; Oscaar

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Banyu; M S Jacovides & Co; Merck & Co; Merck Sharp & Dohme; Neopharmed; S Riesel; sigma-tau SpA
  • Class Antihypertensives; Biphenyl compounds; Heart failure therapies; Imidazoles; Ischaemic heart disorder therapies; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Diabetic nephropathies; Heart failure; Hypertension

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 08 Jun 2012 Merck & Co. completes enrolment in its Phase-III trial for Hypertension (in children and infants aged 6 months to 6 years) in USA, European Union, Latin America, India, Norway, Philippines and Russia (NCT00756938)
  • 26 Jan 2012 Generic equivalent available in Canada for Hypertension & Diabetic nephropathies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top